Cryoport, Inc. CYRX
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy ("CGT") market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies.
We place particular emphasis on the CGT market, our fastest growing market, by delivering highly specialized, end-to-end supply chain solutions that support cell and gene therapy programs from preclinical research, through clinical trials, and ultimately to the global commercialization of approved therapies. As of December 31, 2025, Cryoport supported 760 clinical trials, and 20 commercially approved cell and gene therapies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $176.2M | $156.8M | $168.7M | $237.3M | $222.6M | $78.7M | $33.9M | $19.6M | $12.0M | $7.7M |
| Cost of revenue | $93.1M | $87.1M | $93.3M | $133.4M | $126.0M | $42.4M | $16.6M | $9.4M | $6.0M | $4.6M |
| Gross profit | $83.1M | $69.7M | $75.3M | $103.9M | $96.6M | $36.3M | $17.4M | $10.2M | $6.0M | $3.1M |
| R&D | $17.0M | $17.7M | $18.0M | $15.7M | $16.8M | $9.5M | $3.7M | $1.8M | $1.2M | $598.1K |
| SG&A | $102.8M | $109.8M | $108.3M | $120.1M | $97.6M | $56.9M | $31.3M | $9.8M | $7.4M | $6.4M |
| Total operating expenses | $119.9M | $191.3M | $175.9M | $135.8M | $114.4M | $66.3M | $35.0M | $18.9M | $13.9M | $11.9M |
| Operating income | -$36.8M | -$121.7M | -$100.5M | -$31.9M | -$17.8M | -$30.0M | -$17.7M | -$8.6M | -$7.9M | -$8.8M |
| Interest expense | $2.4M | $4.0M | $5.6M | $6.1M | $4.7M | $2.6M | $1.4M | $69.3K | $15.7K | $139.4K |
| Pre-tax income | -$32.2M | -$104.3M | -$84.2M | -$35.1M | -$273.8M | -$32.7M | -$18.3M | -$9.5M | -$7.9M | -$13.1M |
| Income tax | $1.8M | $359.0K | $345.0K | $2.2M | $1.7M | $45.0K | $62.0K | $20.0K | $5.1K | $5.7K |
| Net income | $78.3M | -$114.8M | -$99.6M | -$37.3M | -$275.5M | -$32.7M | -$18.3M | -$9.6M | -$7.9M | -$13.1M |
| EPS, basic | 1.40 | -2.49 | -2.21 | -0.93 | -6.18 | -1.94 | -0.55 | — | — | — |
| EPS, diluted | 1.40 | -2.49 | -2.21 | -0.93 | -6.18 | -1.94 | -0.55 | -0.34 | -0.34 | -0.93 |
| Shares, diluted (wtd. avg.) | $50.1M | $49.3M | $48.7M | $49.0M | $45.9M | $38.6M | $33.4M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $250.5M | $34.1M | $35.2M | $29.2M | $139.1M | $36.9M | $47.2M | $37.3M | $15.0M | $4.5M |
| Short-term investments | $160.7M | $216.5M | $410.4M | $486.7M | $489.7M | $56.4M | $47.1M | $9.9M | $0 | — |
| Receivables | $33.4M | $25.3M | $42.1M | $43.9M | $39.4M | $31.4M | $7.1M | $3.5M | $1.6M | $1.2M |
| Inventory | $23.2M | $21.5M | $26.2M | $27.7M | $16.5M | $10.5M | $474.0K | $220.5K | $114.8K | $89.5K |
| Total current assets | $476.2M | $341.6M | $535.1M | $604.2M | $693.5M | $147.2M | $103.0M | $51.8M | $17.3M | $6.1M |
| Property, plant and equipment | $85.4M | $80.0M | $84.9M | $63.6M | $49.0M | $30.0M | $11.8M | $4.4M | $2.5M | $1.6M |
| Goodwill | $22.4M | $20.6M | $76.4M | $151.1M | $147.0M | $145.3M | $11.0M | $0 | — | — |
| Other intangibles | $138.1M | $147.9M | $194.4M | $191.0M | $201.4M | $213.9M | $5.2M | $137.2K | $90.6K | $5.0K |
| Total assets | $765.0M | $703.5M | $957.7M | $1.04B | $1.11B | $552.4M | $135.9M | $56.6M | $20.3M | $8.1M |
| Accounts payable | $15.3M | $15.9M | $27.0M | $28.0M | $28.6M | $24.8M | $2.5M | $1.7M | $1.2M | $1.2M |
| Total current liabilities | $219.0M | $64.6M | $45.6M | $40.9M | $42.6M | $35.0M | $5.5M | $3.1M | $2.2M | $2.2M |
| Total liabilities | $262.4M | $301.6M | $468.7M | $482.9M | $471.1M | $169.7M | $9.6M | $18.1M | $2.4M | $2.4M |
| Retained earnings | -$688.9M | -$757.2M | -$642.4M | -$542.8M | -$467.5M | -$192.0M | -$159.3M | -$141.0M | -$131.4M | -$123.5M |
| Total equity | $502.6M | $401.9M | $489.0M | $555.8M | $641.8M | $382.7M | $126.3M | $38.5M | $17.9M | $5.7M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.6M | -$16.3M | -$757.0K | -$1.9M | $8.1M | -$14.9M | -$1.3M | -$3.4M | -$3.6M | -$5.7M |
| Depreciation and amortisation | $27.7M | $30.8M | $27.5M | $22.8M | $20.2M | $9.9M | $2.4M | $857.9K | $664.8K | $374.2K |
| Stock-based compensation | $10.1M | $16.6M | $19.8M | $20.1M | $15.3M | $8.9M | $16.5M | $5.5M | $3.5M | $3.1M |
| Capital expenditure | $16.4M | $17.3M | $38.8M | $22.1M | $23.9M | $8.9M | $5.3M | $2.9M | $1.7M | $1.1M |
| Investing cash flow | $250.3M | $176.8M | $36.0M | -$59.7M | -$469.3M | -$382.3M | -$62.9M | -$12.9M | -$1.8M | -$1.1M |
| Financing cash flow | -$21.1M | -$161.5M | -$23.8M | -$39.2M | $564.3M | $385.6M | $74.2M | $38.5M | $15.9M | $6.1M |
| Buybacks | $10.0M | — | — | $38.0M | $0 | $0 | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016129.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |